Allstate price target raised to $128 from $108 at Barclays

Barclays analyst Tracy Benguigui raised the firm’s price target on Allstate to $128 from $108 and keeps an Equal Weight rating on the shares. On Nov. 1, Allstate shared its intent to sell its Health & Benefits business in 2024, which could potentially command a $3.8B-$4.4B illustrative valuation, the firm pointed out in a research note on Friday.